Defactinib

Generic Name: Defactinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁F_₃N_₈O_₃S

CAS Number: 1073154-85-4

Unique Ingredient Identifier: 53O87HA2QU

Background: Defactinib has been investigated for the treatment of Malignant Pleural Mesothelioma.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combo

Avutometinib and defactinib combo shows 31% overall response rate in recurrent low-grade serous ovarian cancer patients, with 44% in KRAS mutant and 17% in KRAS wild-type. Median progression-free survival is 12.9 months, 22 months in KRAS mutant. Verastem Oncology plans NDA submission in October 2024.

Related Clinical Trials:

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

seekingalpha.com

4 months ago

Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Verastem, Inc. (VSTM) develops cancer treatments targeting the RAS/MAPK pathway, focusing on pancreatic, lung, colorectal, and low-grade serous ovarian cancers. Its leading therapy combines Avutometinib and Defactinib, with a rolling NDA submission expected to finalize by 2H2024 for recurrent LGSOC. VSTM also explores additional indications for metastatic pancreatic cancer and mKRAS G12C NSCLC. The company's tight cash runway makes it a high-risk, high-reward investment, but its current valuation and pathway to approval suggest a bullish outlook.